CIMERLI (ranibizumab-eqrn) — NDC 61314-625 by Sandoz Inc
CIMERLI (ranibizumab-eqrn) — NDC 61314-625 by Sandoz Inc is one of 9,000 drug products in the NDCLookup dataset. Key details — Brand name: CIMERLI; Generic name: ranibizumab-eqrn; Product NDC: 61314-625.
| Brand name | CIMERLI |
|---|---|
| Generic name | ranibizumab-eqrn |
| Product NDC | 61314-625 |
| Labeler | Sandoz Inc |
| Dosage form | INJECTION, SOLUTION |
| Route | INTRAVITREAL |
| Active ingredients | RANIBIZUMAB .5 mg/.05mL |
| Pharmacologic class | Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA] |
| Marketing category | BLA |
| Product type | HUMAN PRESCRIPTION DRUG |
| Source | openFDA NDC Directory |
$899/mo
Try NDCLookup →